Related Experiment Video
Updated: Feb 16, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Antithrombotic stewardship: whether to stop anticoagulation after atrial fibrillation ablation
Lorenz Roger Van der Linden1,2, Qi Shao2, Laura Hellemans3,2
1Hospital Pharmacy Department, University Hospitals Leuven, Leuven, Belgium lorenz.vanderlinden@uzleuven.be.
Insights
Oral anticoagulation (OAC) may not be necessary for select atrial fibrillation (AF) patients after ablation. Recent trials suggest low stroke risk, but limitations exist, requiring careful patient selection before OAC discontinuation.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Growing questions regarding oral anticoagulation (OAC) discontinuation in atrial fibrillation (AF) patients post-ablation.
- Recent trials (ALONE-AF, OCEAN) indicate low stroke rates in selected arrhythmia-free AF patients after ablation.
Purpose of the Study:
- To evaluate the necessity of OAC in AF patients who are arrhythmia-free post-ablation.
- To analyze the findings and limitations of recent trials on OAC discontinuation in this cohort.
Main Methods:
- Review of recent clinical trials (ALONE-AF, OCEAN) investigating OAC use in post-ablation AF patients.
- Critical analysis of study methodologies, patient selection criteria, and statistical power for thromboembolic events.
Main Results:
- Selected post-ablation AF patient cohorts showed low annual stroke rates in recent trials.
- These trials suggest potentially limited added stroke protection from OAC in this specific group.
Conclusions:
- OAC discontinuation may be considered in carefully selected AF patients post-ablation.
- Key criteria include 12-month arrhythmia-free status, low thromboembolic risk, no prior stroke, and intensified monitoring, though validated strategies are lacking.
Abstract:
Hospital pharmacists increasingly receive questions about oral anticoagulation (OAC) discontinuation in patients with atrial fibrillation (AF) who remain arrhythmia-free after ablation. Two recent trials, ALONE-AF and OCEAN, reported low annual stroke rates in selected post-ablation cohorts, suggesting limited added stroke protection from OAC in this group. Both studies have key limitations: selective low-risk patient populations, insufficient power for thromboembolic events, limited external validity to older AF patients, and methodological concerns including ALONE-AF's fragility index and OCEAN's comparator choice. Before OAC discontinuation is considered, multiple criteria should be met: first-time ablation with documented 12 month arrhythmia-free status, low thromboembolic risk, absence of prior cerebrovascular events and access to intensified rhythm monitoring, acknowledging that no validated monitoring strategy currently exists to guide anticoagulation decisions after ablation.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

